Analyst Reco. Edwards Lifesciences Corporation Xetra

Equities

EWL

US28176E1082

Market Closed - Xetra Other stock markets 11:35:41 2024-05-17 am EDT			After market 01:27:02 pm
81.79 ^EUR	-1.53%		81.8	+0.02%

May. 14	Deutsche Bank Upgrades Edwards Lifesciences to Buy From Hold, Raises Price Target to $103 From $86	MT
May. 13	Edwards Lifesciences Insider Sold Shares Worth $439,038, According to a Recent SEC Filing	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Deutsche Bank Upgrades Edwards Lifesciences to Buy From Hold, Raises Price Target to $103 From $86	May. 14	MT
Edwards Lifesciences Insider Sold Shares Worth $439,038, According to a Recent SEC Filing	May. 13	MT
Barclays Adjusts Edwards Lifesciences Price Target to $101 From $100	May. 07	MT
Edwards Lifesciences Insider Sold Shares Worth $1,212,687, According to a Recent SEC Filing	May. 01	MT
Edwards Lifesciences Insider Sold Shares Worth $622,062, According to a Recent SEC Filing	Apr. 30	MT
Bernstein Adjusts Price Target on Edwards Lifesciences to $73 From $72	Apr. 29	MT
Evercore ISI Adjusts Price Target on Edwards Lifesciences to $89 From $92	Apr. 26	MT
Stifel Adjusts Price Target on Edwards Lifesciences to $85 From $83	Apr. 26	MT
Wells Fargo Adjusts Price Target on Edwards Lifesciences to $99 From $94	Apr. 26	MT
UBS Adjusts Edwards Lifesciences Price Target to $95 From $92, Maintains Neutral Rating	Apr. 26	MT
Piper Sandler Adjusts Price Target on Edwards Lifesciences to $88 From $85	Apr. 26	MT
Canaccord Genuity Trims Price Target on Edwards Lifesciences to $85 From $86	Apr. 26	MT
Baird Adjusts Edwards Lifesciences Price Target to $102 From $100	Apr. 17	MT
Leerink Partners Adjusts Edwards Lifesciences' Price Target to $93 From $96, Keeps Market Perform Rating	Apr. 17	MT
ANALYST RECOMMENDATIONS : AMD, Colgate, Fair Isaac, Tyson Foods, AstraZeneca	Apr. 16
Zacks Investment Research Adjusts Price Target on Edwards Lifesciences to $95 From $97	Apr. 15	MT
Truist Securities Adjusts Edwards Lifesciences Price Target to $105 From $97, Buy Rating Kept	Apr. 15	MT
RBC Raises Price Target on Edwards Lifesciences to $101 From $95, Keeps Outperform Rating	Apr. 15	MT
Mizuho Securities Adjusts Price Target on Edwards Lifesciences to $105 From $95, Maintains Buy Rating	Apr. 11	MT
Edwards Lifesciences Insider Sold Shares Worth $1,154,142, According to a Recent SEC Filing	Apr. 08	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Edwards Lifesciences Corporation: The story continues

April 23, 2024 at 11:25 am EDT